Clinical Trial Update: Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of oral encochleated amphotericin B (CAMB/MAT2203) for vulvovaginal candidiasis completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis
• Vulvovaginitis
• Yeast Infection

Drugs mentioned

• CAMB (enzochleated amphotericin B)

Snippet

Sponsor: Matinas BioPharma Nanotechnologies, Inc. | Conditions: Vulvovaginitis, Yeast Infection | Phase 2 | Status: COMPLETED | Results posted: 2018-10-05